9amHealth vs GoodRx
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
9amHealth
Best for Insured patients wanting branded GLP-1s within a full cardiometabolic care programStarting at $149/mo
GoodRx
Best for self-pay brand-name Foundayo and Zepbound KwikPen at retail pharmaciesStarting at $149/mo
Side-by-Side Comparison
| Feature | 9amHealth | GoodRx |
|---|---|---|
| Overall Score | 7.6/10 | ✓8.4/10 |
| Starting Price | $149/mo | $149/mo |
| Editorial Rating | 3.8 ★ /5 | ✓4.2 ★ /5 |
| Features | ✓7 features | 6 features |
| States Available | 0 | ✓50 |
| Compounded | — | — |
| Brand Name | ✓ Yes | ✓ Yes |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
Pros & Cons
9amHealth
Pros
- ✓Prescribes FDA-approved branded GLP-1s (Wegovy, Zepbound, Saxenda)
- ✓$149/month membership or free when covered by insurance
- ✓Membership includes specialists, labs, devices, and medications
- ✓Board-certified obesity specialists (DABOM), endocrinologists, dietitians, PharmDs
- ✓Helps navigate insurance approvals; employer and state-plan partnerships
- ✓Home lab draws available in some areas
- ✓Cardiometabolic whole-body care beyond weight loss
Cons
- ✗Medication coverage and GLP-1 access depend on insurance and BMI criteria
- ✗State availability not enumerated on the public site
- ✗Branded GLP-1s can be costly without insurance coverage
- ✗Pricing for medications not transparently listed
GoodRx
Pros
- ✓$149/month self-pay for brand-name Foundayo (orforglipron) — matches the lowest cash price at launch, far below typical retail
- ✓$299/month self-pay for Zepbound KwikPen — well under Lilly's typical cash list price
- ✓Honored at 70,000+ US pharmacies — the largest retail redemption network of any GLP-1 channel we cover
- ✓No membership fee — bring your own prescription and present the discount card at the pharmacy counter
- ✓Brand-name FDA-approved medication, not compounded
- ✓Manufacturer-direct pricing — Lilly delivers the discount through GoodRx, not a third-party negotiation
- ✓GoodRx Care telehealth offers GLP-1 prescriptions ($39–$70 per visit, $19 with Gold) — one-stop for script plus card
Cons
- ✗Requires a valid prescription — GoodRx is a discount card, not a prescriber; you still need a clinician to write the script
- ✗Self-pay only — does not apply toward insurance benefits or deductibles
- ✗Headline price applies to the lowest Foundayo dose; higher doses may cost more
- ✗No compounded GLP-1 options — not the channel for compounded semaglutide or tirzepatide
- ✗Pricing can change as Lilly's manufacturer coupon program evolves
Our Verdict
GoodRx edges out 9amHealth with a higher overall score of 8.4/10 and is particularly strong for self-pay brand-name Foundayo and Zepbound KwikPen at retail pharmacies. 9amHealth remains a solid alternative, especially if you're looking for Insured patients wanting branded GLP-1s within a full cardiometabolic care program.
Glossary references
Key terms in this article, linked to their canonical definitions.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Related comparisons
Continue exploring 9amHealth and GoodRx head-to-heads in the same category.
- 9amHealth vs CoreAge Rx
- 9amHealth vs TrimRx
- 9amHealth vs Amazon One Medical
- GoodRx vs NovoCare Pharmacy
- GoodRx vs Vytora Health
- GoodRx vs Enhance MD
Or see the full category ranking.
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.